Medication info
Pregalin Capsule 300 mg (Pregabalin)

Pregalin Capsule 300 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›300mg / 1 capsule
Manufacturer / importer
Korea Pharma Co., Ltd.
Appearance
A hard capsule with a brownish-red upper part and a white lower part containing a white powder that is white or light yellow in color
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201800935 · Approved 2018.02.26 · Insurance code 642803070

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, as pregabalin in 2 divided doses per day. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg per day. Based on each patient's response and tolerability, the dose may be increased to 300mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg per day. Based on each patient's response and tolerability, the dose may be increased to 300mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg per day. Based on each patient's response and tolerability, the dose may be increased to 300mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg∼450mg per day. The initial dose is 75mg twice daily (150mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg per day). For patients who do not experience sufficient benefit at a dose of 300mg per day, the dose may be increased within 1 week to 225mg twice daily (450mg per day). Clinical studies have also been conducted at a dose of 600mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the dosing regimen. b: The supplemental dose refers to a dose administered once as an additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12∼17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Korea Pharma Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • secondary generalized symptoms
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used in adults for the treatment of peripheral and central neuropathic pain. It also helps to adjunctively control partial seizures in adults with epilepsy. Additionally, it is effective in alleviating the pain associated with fibromyalgia. Through these efficacies, it is used to improve patients' symptoms and enhance their quality of life.

How to take

Adult dose

This medicine is administered orally, with or without food, as pregabalin in 2 divided doses per day. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg per day. Based on each patient's response and tolerability, the dose may be increased to 300mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg per day. Based on each patient's response and tolerability, the dose may be increased to 300mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg per day. Based on each patient's response and tolerability, the dose may be increased to 300mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg∼450mg per day. The initial dose is 75mg twice daily (150mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg per day). For patients who do not experience sufficient benefit at a dose of 300mg per day, the dose may be increased within 1 week to 225mg twice daily (450mg per day). Clinical studies have also been conducted at a dose of 600mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the dosing regimen. b: The supplemental dose refers to a dose administered once as an additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12∼17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if any mood changes or unusual behaviors occur during treatment, medical personnel should be notified immediately. Patients with hypersensitivity to this drug or those with genetic lactose intolerance should not take this medication. Diabetic patients may need to adjust their dosage of blood glucose control medications due to weight gain. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, the medication should be discontinued immediately. Elderly patients may experience increased dizziness or drowsiness when taking this medication, so caution is needed when starting treatment. Visual blurriness or changes in vision may occur, and these symptoms may improve upon discontinuation of the drug. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be decreased gradually after consultation with medical personnel. Patients with a history of substance abuse may be at higher risk of misuse of this medication and should use it cautiously. Patients with reduced kidney function may require dosage adjustments for this medication. Patients with heart failure should exercise caution in taking this medication, and those with cardiovascular diseases should consult with medical personnel. This medication can cause drowsiness and dizziness, so patients should ensure they are in a stable condition before driving or operating dangerous machinery. In early pregnancy, this medication may pose risks to the fetus, so women who are pregnant or planning to become pregnant should consult with medical personnel and use effective contraception. Lactating women should consider stopping breastfeeding or the medication, as this drug can be transmitted through breast milk. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatment such as hemodialysis may be required if necessary. Keep this medication out of reach of children and avoid transferring it to other containers.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital edema
  • upper airway swelling
  • dizziness
  • drowsiness
Show 187 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • visual changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like symptoms
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • respiratory function impairment
  • respiratory diseases
  • neurological diseases
  • renal disorders
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • elation
  • decreased libido
  • depersonalization
  • paraphilia
  • restlessness
  • anxiety
  • mood swings
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory deficits
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • fasciculations
  • reduced reflexes
  • abnormal movements
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • delirium
  • reduced mobility syndrome
  • olfactory abnormalities
  • taste loss
  • writing difficulties
  • diplopia
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • homogenous bradycardia
  • homogenous tachycardia
  • homogenous arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory deficit
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle twitching
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • drowsiness
  • confusion
  • agitation
  • restlessness
  • seizures
  • shock
  • symptoms resembling anaphylaxis
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is important to store it at a cool temperature between 15 to 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

A hard capsule with a brownish-red upper part and a white lower part containing a white powder that is white or light yellow in color

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.